INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities

Transplant Cell Ther. 2024 Jan;30(1):38-55. doi: 10.1016/j.jtct.2023.10.006. Epub 2023 Oct 10.

Abstract

Chimeric antigen receptor (CAR) T cell (CAR-T) therapy has emerged as a revolutionary cancer treatment modality, particularly in children and young adults with B cell malignancies. Through clinical trials and real-world experience, much has been learned about the unique toxicity profile of CAR-T therapy. The past decade brought advances in identifying risk factors for severe inflammatory toxicities, investigating preventive measures to mitigate these toxicities, and exploring novel strategies to manage refractory and newly described toxicities, infectious risks, and delayed effects, such as cytopenias. Although much progress has been made, areas needing further improvements remain. Limited guidance exists regarding initial administration of tocilizumab with or without steroids and the management of inflammatory toxicities refractory to these treatments. There has not been widespread adoption of preventive strategies to mitigate inflammation in patients at high risk of severe toxicities, particularly children. Additionally, the majority of research related to CAR-T toxicity prevention and management has focused on adult populations, with only a few pediatric-specific studies published to date. Given that children and young adults undergoing CAR-T therapy represent a unique population with different underlying disease processes, physiology, and tolerance of toxicities than adults, it is important that studies be conducted to evaluate acute, delayed, and long-term toxicities following CAR-T therapy in this younger age group. In this pediatric-focused review, we summarize key findings on CAR-T therapy-related toxicities over the past decade, highlight emergent CAR-T toxicities, and identify areas of greatest need for ongoing research.

Keywords: CAR-T toxicities; Chimeric antigen receptor T cell therapy; Cytokine release syndrome; Immune effector cell-associated hematotoxicity; Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome; Immune effector cell-associated neurotoxicity syndrome; Late effects.

Publication types

  • Review

MeSH terms

  • Child
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen* / therapeutic use
  • Risk Factors
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell